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Abstract
Background: Non-small cell lung cancer (NSCLC) and melanoma are frequent entities in routine diagnostics.
Whereas the differential diagnosis is usually straight forward based on histomorphology, it can be challenging in
poorly differentiated tumors as melanoma may mimic various histological patterns. Distinction of the two entities is
of outmost importance as both are treated differently. HMB45 and MelanA are recommended immunohistological
markers for melanoma in this scenario. SOX10 has been described as an additional marker for melanoma. However,
comprehensive large-scale data about the expression of melanoma markers in NSCLC tumor tissue specimen are
lacking so far.
Methods: Therefore, we analyzed the expression of these markers in 1085 NSCLC tumor tissue samples. Tissue
microarrays of NSCLC cases were immunohistochemically stained for HMB45, MelanA, and SOX10. Positivity of a
marker was defined as ≥1% positive tumor cells.
Results: In 1027 NSCLC tumor tissue samples all melanoma as well as conventional immunohistochemical markers
for NSCLC could be evaluated. HMB45, MelanA, and SOX10 were positive in 1 (< 1%), 0 (0%) and 5 (< 1%) cases. The
HMB45 positive case showed co-expression of SOX10 and was classified as large cell carcinoma. Three out of five
SOX10 positive cases were SqCC and one case was an adenosquamous carcinoma.
Conclusions: Expression of HMB45, MelanA and SOX10 is evident but exceedingly rare in NSCLC cases. Together
with conventional immunomarkers a respective marker panel allows a clear-cut differential diagnosis even in poorly
differentiated tumors.
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Background
Non-small cell lung cancer (NSCLC) and melanoma are fre-
quent entities in pathological routine diagnostics. Whereas
the differential diagnosis is often feasible based on his-
tomorphology alone, especially in resection specimens
or when melanin pigment is evident, the distinction of
both can be challenging in small biopsies or cytology
preparations. This is especially true for cases with un-
differentiated morphology as melanoma may mimic
various histological patterns [1]. Although, a tumor
situated in the lung is more likely to be lung cancer, the
lung is a frequent site of metastatic spread especially in
patients with NRAS-mutated melanoma [2, 3] and pri-
mary melanoma of the lung is recognized in the litera-
ture as well [4–6]. Distinction of the two entities is of
outmost importance as both are treated differently [7, 8].
Of note, the common BRAF mutations in melanoma (usu-
ally V600E) [9] can be found in pulmonary adenocarcin-
omas (usually non-V600E) [9–11]. Commonly applied
immunohistological markers in this scenario are S100,
Human Melanoma Black (HMB45), melanoma antigen
recognized by T cells 1 (MelanA), SRY-related
HMG-box 10 (SOX10), cytokeratin 5/6 (CK5/6), NapsinA,
p63 (p40) and thyroid transcription factor-1 (TTF-1)
[12, 13]. While the expression of CK5/6, NapsinA, p63
and TTF-1 has been extensively studied in NSCLC [14, 15]
and the immunoreactivity of S100, HMB45, MelanA
and SOX10 is well described for melanoma [16], the
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comprehensive expression of melanoma markers in
NSCLC has not been analyzed in a large NSCLC tumor
tissue cohort to date, except for S100 [17]. This is surpris-
ing as especially SOX10 has prompted recent interest and
has been reported in various other cancer entities.
Therefore, we systematically analyzed the expression of
HMB45, MelanA, SOX10, CK5/6, NapsinA, p63 and
TTF-1 in 1027 NSCLC cases including 498 adenocar-
cinomas (ADC), 424 squamous cell carcinomas (SqCC),
44 adenosquamous carcinomas (ADSqCC), 51 large cell
carcinomas (LC) and 10 pleomorphic carcinomas (PC).
Methods
Cohort characteristics
Formalin-fixed and paraffin embedded NSCLC tumor
tissue specimens resected from 2004 to 2007 in the
Thoracic Hospital Heidelberg were extracted from the
archive of the Institute of Pathology, Heidelberg University,
with the support of the tissue bank of the National Center
for Tumor Diseases (#2508, ethics committee University of
Heidelberg #S-205). Tissues were used in accordance with
the ethical regulations of the NCT tissue bank defined by
the local ethics committee and according to the Declaration
of Helsinki. Diagnoses were made according to the recom-
mendations of the World Health Organization classification
for lung cancer 2015 [12]. A cohort of 1085 NSCLC cases
was selected. Tissue microarray construction was done as
described previously [15, 18, 19]. The results from the
conventional NSCLC markers CK5/6, NapsinA, p63 and
TTF-1 were stained and published previously [15]. A
detailed description of the clinical characteristics of the
NSCLC tumor tissue cohort is provided in Table 1.
Immunohistochemistry
Immunohistochemical staining was performed as previ-
ously described [20]. In brief, slides were deparaffinized,
pre-treated with an antigen retrieval buffer and stained
using an automated device. Conventional NSCLC markers
were stained on a Techmate 500plus (Dako, Hamburg,
Germany) and melanoma-markers on a Ventana Bench-
mark Ultra (Roche, Rotkreuz, Switzerland). The antibody
and staining characteristics are shown in Table 2. Staining
was evaluated based on positivity of > 1% positive tumor
cells by an experienced pathologist (M.K.). The cut-off of
1% positive tumor cells was chosen to avoid classification
of minimal staining (which would likely be background
staining) as positive. Typical examples of positive and
negative samples of the respective antibodies are shown
in Fig. 1.
Data analysis and software
All statistical analyses were done in R-Statistical Software
(www.r-project.org, v.3.4.2, Free Software Foundation)
and R-Studio (v.1.1.383, Affero General Public License,
Boston, USA). The Figure was created in Inkscape
(v. 0.92) and Powerpoint (Microsoft, Redmond, USA).
Results
Evaluation of tissue microarrays
In a total of 1027 NSCLC tumor tissue specimen HMB45,
MelanA, SOX10, CK5/6, NapsinA, p63, and TTF-1 could
be evaluated. In the other cases one or more of the con-
ventional stainings (CK5/6, NapsinA, p63 and TTF-1)
could not be analyzed due to floating or rolling of tissue
cores. The drop-out rate was 5%. All neglected cases were
negative for HMB45, MelanA and SOX10.
Table 1 Clinical characteristics of the cohort
Patients, n 1027
Median age, years (range) 64 (30–85)
Patient gender n (%)
Male 734 (71)
Female 293 (29)
Histology
ADC 498 (48)
SqCC 424 (41)
ADSqCC 44 (4)
LC 51 (5)
PC 10 (1)
TNM-Classification
pT1a 84 (8)
pT1b 114 (11)
pT2a 484 (47)
pT2b 170 (17)
pT3 155 (15)
pT4 20 (2)
pN0 503 (49)
pN1 244 (24)
pN2 249 (24)
pN3 6 (1)
pNX 25 (2)
pM1 25 (2)
pM0 1002 (98)
Clinical stage
IA 133 (13)
IB 255 (25)
IIA 209 (20)
IIB 105 (10)
IIIA 286 (28)
IIIB 14 (1)
IV 25 (2)
ADC, adenocarcinoma, ADSqCC, adenosquamous carcinoma, LC, large cell
carcinoma, n, number, SqCC, squamous cell carcinoma
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Expression of conventional NSCLC markers CK5/6, NapsinA,
p63, and TTF-1
CK5/6, NapsinA, p63 and TTF-1 were positive in 457
(44%), 409 (40%), 510 (50%) and 502 (49%) cases, respect-
ively. While CK5/6 and p63 were most commonly expressed
in SqCC (403 (95%) and 405 (95%)), NapsinA and TTF-1
were mainly positive in ADC (371 (74%) and 436 (88%)).
Expression of melanoma markers HMB45, MelanA, and
SOX10 and interplay with conventional NSCLC markers
HMB45, MelanA, and SOX10 were positive in 1 (< 1%), 0
(0%) and 5 (< 1%) of cases respectively. The HMB45
positive case showed co-expression of SOX10. This par-
ticular case was also positive for AE1/3, CK7, CK5/6
(focal). NapsinA, TTF-1, p40, p63, CD56, synaptophy-
sin, S100 as well as MelanA were negative. Based on
morphology and immunohistochemistry this sample was
classified as LC. All of the five SOX10 positive cases were
also positive for CK5/6, three were positive for p63 and all
were negative for NapsinA and TTF-1. Three out of five
SOX10 positive cases were classified as SqCC, one was
classified as ADSqCC based on the resection specimen.
The other histological subtypes (ADC or PC) showed no
expression of melanoma markers.
Table 2 Antibodies used in this study and staining conditions
Antibody Company Clone Pretreatment Buffer incubation
time (min)
Antibody incubation
time (min)
Dilution
CK5/6 Dako D5/16 B4 Tris/Borat/EDTA, pH 9 56 24 1:50
HMB45 Dako HMB45 Tris/Borat/EDTA, pH 8.4 64 24 1:75
MelanA Ventana A103 Tris/Borat/EDTA, pH 8.4 64 24 RTU
SOX10 Cell Marque EP268 Tris/Borat/EDTA, pH 8.4 48 24 1:100
Napsin A Novocastra IP64 Tris/Borat/EDTA, pH 6 32 24 1:400
p63 DCS Immunoline 4A4 Tris/Borat/EDTA, pH 6 40 24 1:25
TTF-1 Novocastra SPT24 Tris/Borat/EDTA, pH 9 56 24 1:200
CK, cytokeratin, HMB45, Human Melanoma Black 45, SOX10, SRY-related HMG-box 10 protein, TTF-1, thyroid transcription factor-1
A B C
D E F
Fig. 1 Examples of immunohistochemical stainings. Positive (a-c) and negative (d-f) examples of HMB45 (a, d) and SOX10 (b, c, f) are displayed. A
representative image of a negative MelanA stain (e) in SqCC is also demonstrated. SOX10 expression reached from strong expression in all tumor
cells (b) to focal positivity in only a subset of cells (c). Mag.: 200×. HMB45, Human Melanoma Black 45, SqCC, squamous cell carcinoma, SOX10,
SRY-related HMG-box 10 protein
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Discussion
As novel targeted therapies for melanoma and NSCLC
are available which show impressive effects, the differen-
tiation of both entities is essential. However, little is
known about the expression of melanoma markers in
NSCLC tissue specimens, except for S100 [17]. In the
present study we analyzed HMB45, MelanA, SOX10,
CK5/6, NapsinA, p63, and TTF-1 in a large cohort of
NSCLC cases and demonstrate that expression of melan-
oma markers is rare. A small subset of SqCC, LC and
ADSqCC may be positive for SOX10.
HMB45 is a monoclonal antibody that has been first
described in 1986 [21] and recognizes melanosomal
glycoprotein gp100 (Pmel17). The anti-MelanA murine
monoclonal antibody A103 [22] has been described in
the late 1990s. Both are commonly applied in thoracic
pathology for the detection of melanocytic tumors [2, 13],
and to exclude rare thoracic tumors such as perivascular
epitheloid cell tumors (PEComa) including lymphangio-
leiomyomatosis [23] or clear cell sugar tumor [24] as well
as for the diagnosis of clear cell sarcoma of soft parts
[25]. Besides its role in the differential diagnosis of
thoracic tumors, HMB45 and MelanA expression has
been demonstrated in sex-chord stromal tumors [26],
t(6;11)(p21;q12)-translocation associated renal cell neo-
plasms [27], endometrial stromal sarcomas [28] and nerve
sheet tumors [29].
A more recently described melanocytic immunomar-
ker is SOX10 which regulates Wnt/β-catenin signaling,
contributes to stem/progenitor activity and induces a
mesenchymal transition expression [30, 31]. It has been
suggested to be a useful marker for the differential diagno-
sis of melanocytic lesions [32, 33]. However, expression of
SOX10 has also been recently described in benign adnexal
skin tumors such as cylindroma and spiradenoma (uni-
formly positive) [34], schwannoma [33], in tumors of
myoepithelial origin [33] and in a subset of malignant neo-
plasms for instance bladder cancer [35], breast cancer
[36], ependymoma [37], gastric adenocarcinoma [38], he-
patocellular carcinoma [39], nasopharyngeal carcinoma
[40], ovarian tumors [41], prostate cancer [42], salivary
gland tumors [43, 44], and squamous cell carcinoma
of head and neck [33]. SOX10 positivity is usually re-
stricted to a small subset of carcinomas (< 10%) except
for triple-negative breast cancer that may more frequently
express SOX10 [33].
To the best of our knowledge, HMB45, MelanA and
SOX10 expression has not been evaluated in a large
NSCLC cohort > 1000 samples so far and has been investi-
gated only in a limited number of patients [45]. The later
study included five normal lung samples and 25 neo-
plastic lung cancer samples, all of which were negative
for SOX10. Miettinen et al. reported occasional SOX10
expression in SqCC of lungs and in one well-differentiated
fetal pulmonary ADC, but they did not specify the num-
ber of positive SqCC cases, nor the overall number of lung
cancer samples analyzed. In line with the expression of
SOX10 in myoepithelial and basal cells, a subset of pul-
monary SqCC have been described to be positive for the
basal type cytokeratin CK15 [46]. However, the biological
role of the expression of basal cell markers in NSCLC tis-
sue specimen remains to be investigated. In our study we
found only one HMB45 positive case classified as LC,
which had co-expression of SOX10. SOX10 positivity was
observed in five out of 1085 cases. Three of them were
SqCC and one case was ADSqCC. None of the ADC or
PC showed expression of melanocytic markers.
Conclusions
In summary, we demonstrate in a large NSCLC tumor
tissue cohort that expression of HMB45, MelanA, and
SOX10 is exceedingly rare in NSCLC cases and almost
restricted to tumors with squamous differentiation.
Thus, together with the conventional immunomarkers for
NSCLC, a marker panel including these stainings is valu-
able in the differential diagnosis of thoracic neoplasms
and melanoma and will lead to a definite diagnosis even in
poorly differentiated tumors.
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